Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Bayly

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Atherosclerosis|January 15, 2020
Corrigendum to "Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017" [Atherosclerosis 290 (November 2019) 44-51]Alison Pottle, Gilbert Thompson, Mahmoud Barbir, et al.
Atherosclerosis|November 15, 2016
HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United KingdomMichael France, Alan Rees, Dev Datta, et al.
Science Translational Medicine|August 11, 2017
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Yuk-Fun Liu, Sefina Arif, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Atherosclerosis|January 15, 2020
Corrigendum to "Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017" [Atherosclerosis 290 (November 2019) 44-51]Alison Pottle, Gilbert Thompson, Mahmoud Barbir, et al.
Atherosclerosis|November 15, 2016
HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United KingdomMichael France, Alan Rees, Dev Datta, et al.
Science Translational Medicine|August 11, 2017
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Yuk-Fun Liu, Sefina Arif, et al.
Pageof 2